GLUCOSE-6-PHOSPHATE DEHYDROGENASE VARIANTS IN JAPAN  This study was supported in part by research grants from the Ministry of Education, Science and Culture and Ministry of Health and Welfare, Japan.

Shiro, Motoo; Fujii, H.

doi:10.1016/b978-0-12-772640-3.50018-4

Glucose-6-Phosphate Dehydrogenase 1986

DOI: 10.1016/b978-0-12-772640-3.50018-4

|View full text |Cite

GLUCOSE-6-PHOSPHATE DEHYDROGENASE VARIANTS IN JAPAN This study was supported in part by research grants from the Ministry of Education, Science and Culture and Ministry of Health and Welfare, Japan.

Motoo Shiro

H. Fujii

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1995

1996

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: Tabulation of mutant enzymes

Shiro¹,

Fujii²

1996

American J Hematol

Self Cite

View full text Add to dashboard Cite

Molecular abnormalities of erythroenzymopathies associated with hereditary hemolytic anemia have been determined by means of molecular biology. Pyruvate kinase (PK) deficiency is the most common and well-characterized enzyme deficiency in the glycolytic pathway, and it causes hereditary hemolytic anemia. To date, 47 gene mutations have been identified. We identified one base deletion, one splicing mutation, and six distinct missense mutations in 12 unrelated families with a homozygous PK deficiency. Mutations located near the substrate or fructose-1,6- diphosphate binding site may change the conformation of the active site, resulting in a drastic loss of activity and severe clinical symptoms. Glucose-6-phosphate dehydrogenase (G6PD)deficiency is the most common metabolic disorder, and it is associated with chronic hemolytic anemia and/or drug- or infection-induced acute hemolytic attack. An estimated 400 million people are affected worldwide. The mutations responsible for about 78 variants have been determined. Some have polymorphic frequencies in different populations. Most variants are produced by one or two nucleotide substitutions. Molecular studies have disclosed that most of the class 1 G6PD variants associated with chronic hemolysis have the mutations surrounding either the substrate or the NADP binding site. Among rare enzymopathies, missense mutations have been determined in deficiencies of glucosephosphate isomerase, (TPI), phosphoglycerate kinase, and adenylate kinase. Compound heterozygosity with missense mutation and base deletion has been determined in deficiencies of hexokinase and diphosphoglyceromutase. Compound heterozygosity with missense and nonsense mutations has been identified in TPI deficiency. One base junction mutations resulting in abnormally spliced PFK-M mRNA have been identified in homozygous PFK deficiency. An exception is hemolytic anemia due to increased adenosine deaminase activity. The basic abnormality appears to result from the overproduction of a structurally normal enzyme.

show abstract

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: Tabulation of mutant enzymes

Shiro¹,

Fujii²

1996

American J Hematol

Self Cite

View full text Add to dashboard Cite

show abstract

Haptoglobin therapy for acute favism: a Japanese boy with glucose‐6‐phosphate dehydrogenase Guadalajara

et al. 1995

View full text Add to dashboard Cite

We report the case of a 2-year-old Japanese boy with acute favism who was treated with human haptoglobin products. He had been exhibiting chronic nonspherocytic haemolytic anaemia until the diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency when 14 months old. He suffered a favic crisis at 24 months of age, when the administration of haptoglobin was effective for relieving bilirubinaemia and haemoglobinuria. Serum-free Hb rapidly decreased to normal levels despite the sustained level of serum lactate dehydrogenase. His G6PD gene was G6PD Guadalajara. This is the first application of haptoglobin therapy for acute favism and the first reported case of Japanese G6PD deficiency with typical favic crisis. Haptoglobin treatment might be helpful for managing the haemolytic crisis in the disease.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

GLUCOSE-6-PHOSPHATE DEHYDROGENASE VARIANTS IN JAPAN This study was supported in part by research grants from the Ministry of Education, Science and Culture and Ministry of Health and Welfare, Japan.

Cited by 2 publications

References 16 publications

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: Tabulation of mutant enzymes

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: Tabulation of mutant enzymes

Haptoglobin therapy for acute favism: a Japanese boy with glucose‐6‐phosphate dehydrogenase Guadalajara

Contact Info

Product

Resources

About